~~<i id='C3BF1108D3'><strike id='C3BF1108D3'><tt id='C3BF1108D3'><pre id='C3BF1108D3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：focus 2025-10-02 06:02:37 - browse：99943

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Three trends to watch in biotech in 2024

focus

knowledge

hotspot

explore

hotspot

AdobeEveryoneknowsthattheUnitedStatesistheonlyhigh-incomecountrywithoutuniversalhealthinsurance.Acco

WSS

The mammogram wars are not over

Keeping primary care docs in field isn't impossible, says AAFP CEO

Marc Tessier

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

VC firm RA Capital starts a new synthetic biology incubator

focus

entertainment

focus

23andMe had bad news about my health. I wish a person had delivered it

What STAT readers think about the FDA and patient advocacy

State Dept. review finds Biden bears some blame for Afghanistan failures

Ford recalls 870K F

Heart attack and stroke risk calculators need revising

Will biotech layoffs continue through 2023?

The cancer drug shortage isn’t new — and neither are the solutions

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Jerome Adams on the need for new antivirals for Covid

How to keep neuroscience’s past racism from being its future

knowledge

Violet CEO on training clinicians to promote more inclusive care

Why health records don't always know when patients are dead

Behind warning on Apellis’s eye drug lies a conflict of interest

How to keep neuroscience’s past racism from being its future

CDC: Cases of alpha

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

knowledge

hotspot

explore

hotspot